collection
Collections Vaptans, Acuaresis and Syndrom...

Vaptans, Acuaresis and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

https://read.qxmd.com/read/37966286/arginine-or-hypertonic-saline-stimulated-copeptin-to-diagnose-avp-deficiency
#1
JOURNAL ARTICLE
Julie Refardt, Cihan Atila, Irina Chifu, Emanuele Ferrante, Zoran Erlic, Juliana B Drummond, Rita Indirli, Roosmarijn C Drexhage, Clara O Sailer, Andrea Widmer, Susan Felder, Andrew S Powlson, Nina Hutter, Deborah R Vogt, Mark Gurnell, Beatriz S Soares, Johannes Hofland, Felix Beuschlein, Martin Fassnacht, Bettina Winzeler, Mirjam Christ-Crain
BACKGROUND: Distinguishing between arginine vasopressin (AVP) deficiency and primary polydipsia is challenging. Hypertonic saline-stimulated copeptin has been used to diagnose AVP deficiency with high accuracy but requires close sodium monitoring. Arginine-stimulated copeptin has shown similar diagnostic accuracy but with a simpler test protocol. However, data are lacking from a head-to-head comparison between arginine-stimulated copeptin and hypertonic saline-stimulated copeptin in the diagnosis of AVP deficiency...
November 16, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37851876/the-syndrome-of-inappropriate-antidiuresis
#2
REVIEW
Horacio J Adrogué, Nicolaos E Madias
New England Journal of Medicine, Volume 389, Issue 16, Page 1499-1509, October 2023.
October 19, 2023: New England Journal of Medicine
https://read.qxmd.com/read/37007374/clinical-approach-to-euvolemic-hyponatremia
#3
REVIEW
Pramod Reddy
Euvolemic hyponatremia is frequently encountered in hospitalized patients and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most common cause in most patients. SIADH diagnosis is confirmed by decreased serum osmolality, inappropriately elevated urine osmolality (>100 mosmol/L), and elevated urine sodium (Na) levels. Patients should be screened for thiazide use and adrenal or thyroid dysfunction should be ruled out before making a diagnosis of SIADH. Clinical mimics of SIADH like cerebral salt wasting and reset osmostat should be considered in some patients...
February 2023: Curēus
https://read.qxmd.com/read/36974717/syndrome-of-inappropriate-antidiuresis-from-pathophysiology-to-management
#4
JOURNAL ARTICLE
Annabelle M Warren, Mathis Grossmann, Mirjam Christ-Crain, Nicholas Russell
Hyponatremia is the most common electrolyte disorder, affecting more than 15% of patients in hospital. The syndrome of inappropriate anti-diuresis (SIAD) is the most frequent cause of hypotonic hyponatremia, mediated by non-osmotic release of arginine vasopressin (AVP, previously known as anti-diuretic hormone (ADH)) which acts on the renal V2 receptors to promote water retention. There are a variety of underlying causes of SIAD, including malignancy, pulmonary pathology and central nervous system pathology...
March 28, 2023: Endocrine Reviews
https://read.qxmd.com/read/36823952/novel-signaling-pathways-in-nephrogenic-syndrome-of-inappropriate-antidiuresis-functional-implication-of-site-specific-aqp2-phosphorylation
#5
JOURNAL ARTICLE
Maria Venneri, Vanessa Vezzi, Annarita Di Mise, Marianna Ranieri, Mariangela Centrone, Grazia Tamma, Lene N Nejsum, Giovanna Valenti
Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) is a rare X-linked disease caused by gain-of-function mutations of the V2 vasopressin receptor (V2R). NSIAD patients are characterized by the inability to excrete a free water load and inappropriately increased urinary osmolality despite very low levels of plasma vasopressin resulting in euvolemic hyponatremia. To dissect the signaling downstream V2R constitutively active variants, Flp-In T-REx Madin-Darby canine kidney (FTM) cells, stably transfected with V2R mutants (R137L, R137C, and F229V) and AQP2-wt or non-phosphorylatable AQP2-S269A/AQP2-S256A, were used as cellular models...
February 23, 2023: Journal of Physiology
https://read.qxmd.com/read/36752971/impact-of-urine-cyclic-amp-relative-to-plasma-arginine-vasopressin-on-response-to-tolvaptan-in-patients-with-chronic-kidney-disease-and-heart-failure
#6
JOURNAL ARTICLE
Kota Kakeshita, Tsutomu Koike, Teruhiko Imamura, Hayato Fujioka, Hidenori Yamazaki, Koichiro Kinugawa
BACKGROUND: The clinical utility of tolvaptan in chronic kidney disease (CKD) patients with heart failure remains uncertain. The level of urine cyclic adenosine monophosphate (AMP) relative to plasma arginine vasopressin (AVP) indicates the residual function of the collecting ducts in response to AVP stimulation and might be a key to predicting response of tolvaptan. METHODS: CKD patients who were hospitalized to treat their congestive heart failure refractory to conventional loop diuretics were considered to receive tolvaptan and included in this prospective study...
February 8, 2023: Clinical and Experimental Nephrology
https://read.qxmd.com/read/36656532/long-term-efficacy-of-empagliflozin-as-an-add-on-treatment-for-chronic-siad-a-case-report-and-literature-review
#7
REVIEW
Fabio Bioletto, Emanuele Varaldo, Nunzia Prencipe, Andrea Benso, Alessandro Maria Berton
BACKGROUND: SLGT-2 inhibitors have recently been investigated as a promising therapy for syndrome of inappropriate antidiuresis (SIAD). However, to our knowledge, no report has been published about their use for this indication in the long term. CASE PRESENTATION: We report the case of a 68-year-old male with type 2 diabetes and chronic SIAD, in whom serum sodium levels were not adequately controlled by urea monotherapy. Other treatment options were not viable due to inefficacy or adverse effects...
June 2023: Hormones: International Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/36396331/treatment-effect-of-the-sglt2-inhibitor-empagliflozin-on-chronic-syndrome-of-inappropriate-antidiuresis-results-of-a-randomized-double-blind-placebo-controlled-crossover-trial
#8
RANDOMIZED CONTROLLED TRIAL
Julie Refardt, Cornelia Imber, Rianne Nobbenhuis, Clara O Sailer, Aaron Haslbauer, Sophie Monnerat, Cemile Bathelt, Deborah R Vogt, Manfred Berres, Bettina Winzeler, Stephanie A Bridenbaugh, Mirjam Christ-Crain
BACKGROUND: The syndrome of inappropriate antidiuresis (SIAD) is characterized by a reduction of free water excretion with consecutive hypotonic hyponatremia and is therefore challenging to treat. The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion, likely leading to increased electrolyte free water clearance. METHODS: In this randomized, double-blind, placebo-controlled, crossover trial, we compared 4-week treatment with empagliflozin 25 mg/d to placebo in outpatients with chronic SIAD-induced hyponatremia...
February 1, 2023: Journal of the American Society of Nephrology: JASN
https://read.qxmd.com/read/35916355/benefits-of-tolvaptan-on-early-dyspnea-relief-in-patients-with-acute-heart-failure-a-meta-analysis
#9
REVIEW
Wenli Shang, Yingying Zhang, Dong Han
Considering the prevalence of dyspnea in acute heart failure (AHF), its reduction is important to both patients and caregivers. This meta-analysis was performed to determine the efficacy and safety of tolvaptan on early dyspnea relief in patients with AHF. A systematic search was made of PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of AHF with tolvaptan, compared with placebo or blank, were reviewed...
October 2022: Clinical Cardiology
https://read.qxmd.com/read/35590283/syndrome-of-inappropriate-antidiuretic-hormone-secretion-is-associated-with-different-proton-pump-inhibitor-use-a-pharmacovigilance-study
#10
JOURNAL ARTICLE
Mengmeng Wang, Lingjian Zhang, Min Jia, Junyan Wang, Zhiwen Shen, Shuyue Wang, Xinghui Zhang, Jing Xu, Zheng Zheng, Xuanrui Lv, Xiaoyu Zong, Hui Li, Jin Zhou, Tong Meng, Mingzhu Chen, Bin Zhao, Jian Gong
AIM: The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: FAERS reports from January 2004 to March 2020 were used to conduct disproportionality and Bayesian analyses. The definition of SIADH relied on the preferred terms provided by the Medical Dictionary for Regulatory Activities...
May 19, 2022: BMC Nephrology
https://read.qxmd.com/read/34586414/vaptans-or-voluntary-increased-hydration-to-protect-the-kidney-how-do-they-compare
#11
JOURNAL ARTICLE
Lise Bankir, Dominique Guerrot, Daniel G Bichet
The adverse effects of vasopressin (AVP) in diverse forms of chronic kidney disease have been well described. They depend on the antidiuretic action of AVP mediated by V2 receptors (V2R). Tolvaptan, a selective V2R antagonist, is now largely used for the treatment of patients with autosomal dominant polycystic kidney disease. Another way to reduce the adverse effects of AVP is to reduce endogenous AVP secretion by a voluntary increase in fluid intake. These two approaches differ in several ways, including the level of thirst and AVP...
February 28, 2023: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/34238461/the-vasopressin-aquaporin-2-pathway-syndromes
#12
REVIEW
Giovanna Valenti, Grazia Tamma
Vasopressin is the key hormone involved in water conservation and regulation of water balance, essential for life. In the renal collecting duct, vasopressin binds to the V2 receptor, increasing water permeability through activation of aquaporin-2 redistribution to the luminal membrane. This mechanism promotes rapid water reabsorption, important for immediate survival; however, only recently it has become clear that long-term adverse effects are associated with alterations of the vasopressin-aquaporin-2 pathway, leading to several syndromes associated with water balance disorders...
2021: Handbook of Clinical Neurology
https://read.qxmd.com/read/34236307/variations-in-daily-urine-solute-output-in-patients-with-ndi-cdi-siadh-and-nsiad-clinical-implications
#13
JOURNAL ARTICLE
Guy Decaux
INTRODUCTION: We aimed to study the effects of daily variation in solute intake on urine volume in patients with syndrome of inappropriate secretion of antidiuretic hormone secretion (SIADH), syndrome of nephrogenic antidiuresis (NSIAD), central diabetes insipidus (CDI), or nephrogenic diabetes insipidus (NDI). MATERIALS AND METHODS: In 6 patients with CDI, 7 patients with NDI, 7 patients with SIADH, and 2 patients with NSIAD we had the opportunity to have 24-hour urine collections during normal diet before any treatment...
October 2021: Clinical Nephrology
https://read.qxmd.com/read/33904139/efficacy-of-oral-tolvaptan-for-severe-edema-and-hyponatremia-in-a-patient-with-refractory-nephrotic-syndrome
#14
JOURNAL ARTICLE
Mari Saimiya, Yoshitsugu Kaku, Manao Nishimura
Tolvaptan (TLV) is a vasopressin V2 receptor antagonist that increases free water excretion. However, there are few reports of the use of TLV in pediatric patients with nephrotic syndrome (NS). The efficacy of TLV for the management of edema and hyponatremia in a 12-year-old boy with refractory NS is demonstrated. In this patient, refractory NS developed at 5 years of age, and remission was maintained with several immunosuppressive agents. He was admitted to hospital due to relapse with oliguria, edema, hypoalbuminemia, and hyponatremia...
November 2021: CEN Case Reports
https://read.qxmd.com/read/33625806/-clinical-use-of-tolvaptan-a-2021-review
#15
REVIEW
Olivier Bonny, Pierre-Yves Martin, Fabien Stucker
Along with the arrival of the first vasopressin-receptor V2R inhibitor, the indications for its use have increased. We review here and focus on polycystic kidney disease (PKD) and hyponatremia. Tolvaptan is the first drug available to slow down the progression of PKD in patients with rapid progressing disease. However, the benefits are moderate and the side effects are important, making important to share the decision of treatment together with the patient. Hyponatremia with preserved extra-cellular volume or associated with edema may be reversed by tolvaptan...
February 24, 2021: Revue Médicale Suisse
https://read.qxmd.com/read/33477721/the-biology-of-vasopressin
#16
REVIEW
Samantha Sparapani, Cassandra Millet-Boureima, Joshua Oliver, Kathy Mu, Pegah Hadavi, Tamar Kalostian, Nazifa Ali, Carla Maria Avelar, Marion Bardies, Brenton Barrow, Minky Benedikt, Giuliana Biancardi, Raminder Bindra, Lisa Bui, Zakaria Chihab, Ashley Cossitt, Jeffrey Costa, Tina Daigneault, Jocelyn Dault, Isa Davidson, Jonathan Dias, Emie Dufour, Sabine El-Khoury, Nargess Farhangdoost, Anika Forget, Alexa Fox, Myriam Gebrael, Maria Concetta Gentile, Olivia Geraci, Ansley Gnanapragasam, Elias Gomah, Elie Haber, Claudia Hamel, Thivya Iyanker, Christina Kalantzis, Sara Kamali, Elsa Kassardjian, Hryssi Krissy Kontos, Thi Bich Uyen Le, Daniella LoScerbo, Yan Fang Low, Danielle Mac Rae, Flore Maurer, Sana Mazhar, Alice Nguyen, Kathy Nguyen-Duong, Chelsea Osborne-Laroche, Hwi Wun Park, Emilie Parolin, Kahlila Paul-Cole, Leah Sarah Peer, Margaux Philippon, Charles-Alexandre Plaisir, Jessica Porras Marroquin, Simran Prasad, Rewaparsad Ramsarun, Saad Razzaq, Samantha Rhainds, Damien Robin, Ryan Scartozzi, Davindra Singh, Sajad Soleimani Fard, Maxim Soroko, Nastaran Soroori Motlagh, Kiri Stern, Laila Toro, M Wyatt Toure, Stephanie Tran-Huynh, Sarah Trépanier-Chicoine, Claudia Waddingham, Aaliyah Jasmine Weekes, Allison Wisniewski, Chiara Gamberi
Vasopressins are evolutionarily conserved peptide hormones. Mammalian vasopressin functions systemically as an antidiuretic and regulator of blood and cardiac flow essential for adapting to terrestrial environments. Moreover, vasopressin acts centrally as a neurohormone involved in social and parental behavior and stress response. Vasopressin synthesis in several cell types, storage in intracellular vesicles, and release in response to physiological stimuli are highly regulated and mediated by three distinct G protein coupled receptors...
January 18, 2021: Biomedicines
https://read.qxmd.com/read/33336480/risks-of-vaptans-in-hypernatremia-and-serum-sodium-overcorrection-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials
#17
REVIEW
Ya Zhou, Wenru Yang, Guotao Liu, Weiyi Gao
OBJECTIVE: Serum sodium overcorrection and hypernatremia are significant health risks. We conducted a systematic review and meta-analysis to evaluate the risks of vaptans in hypernatremia and serum sodium overcorrection. METHODS: We searched PubMed, Embase, and CENTRAL for randomised controlled trials. We included studies comparing vaptans and placebo with data on hypernatremia and serum sodium overcorrection. The study quality was assessed using the Cochrane Collaboration's risk-of-bias assessment tool...
June 2021: International Journal of Clinical Practice
https://read.qxmd.com/read/32946431/syndrome-of-inappropriate-antidiuretic-hormone-siadh-induced-by-long-term-use-of-citalopram-and-short-term-use-of-naproxen
#18
JOURNAL ARTICLE
Chia-Yu Chiu, Amara Sarwal, Rehan Azhar Munir, Michael Widjaja, Amna Khalid, Rajan Khanna
BACKGROUND Use of selective serotonin reuptake inhibitors (SSRIs) has been reported to be associated with the syndrome of inappropriate antidiuretic hormone (SIADH), although it is uncommon. Nonsteroidal anti-inflammatory drugs (NSAIDs), as a sole agent, are an even rarer cause of SIADH. Despite being documented in the literature, the understanding of the mechanism of both agents is limited. Here, we report a case of a patient taking both of these medications, a dangerous combination that led to the development of SIADH...
September 18, 2020: American Journal of Case Reports
https://read.qxmd.com/read/32869173/tolvaptan-treatment-in-hyponatremia-due-to-the-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone-siadh-effects-on-survival-in-patients-with-cancer
#19
MULTICENTER STUDY
Irem Bilgetekin, Ismail Erturk, Fatma Bugdayci Basal, Cengiz Karacin, Nuri Karadurmus, Berna Oksuzoglu, Umut Demirci
PURPOSE: To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival METHODS: This study included oncology patients who were hospitalized at two oncology centers between January 1, 2016 and December 31, 2019 for hyponatremia (sodium levels < 135 mEq/L) and who received tolvaptan plus supportive treatment (n = 22) or supportive treatment only (n = 42)...
February 2021: International Urology and Nephrology
https://read.qxmd.com/read/32863282/open-label-multicenter-dose-titration-study-to-determine-the-efficacy-and-safety-of-tolvaptan-in-japanese-patients-with-hyponatremia-secondary-to-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone
#20
JOURNAL ARTICLE
Hiroshi Arima, Koichi Goto, Tomohisa Motozawa, Makoto Mouri, Ryo Watanabe, Takahiro Hirano, San-E Ishikawa
The purpose of this study was to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone (SIADH). This multicenter, open-label, dose-escalation, phase III study enrolled Japanese patients (20-85 years old) with hyponatremia secondary to SIADH who were unresponsive to fluid restriction. Oral tolvaptan was administered for up to 30 days, initially at 7.5 mg/day, but escalated daily as necessary, based on the serum sodium concentration and safety, over the first 10 days until the optimal maintenance dose was determined for each patient (maximum 60 mg/day)...
August 29, 2020: Endocrine Journal
label_collection
label_collection
1617
1
2
2020-09-02 21:47:36
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.